Adicet Bio, Inc.

Adicet Bio, Inc. is a biotechnology company, which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. It also focuses on developing a pipeline of “off-the-shelf” gamma delta T cells. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.

MENLO PARK, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that an abstract detailing updated safety and efficacy data from the Company's Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphoma (NHL) was made available as part of the 2022 Americ

Adicet Bio Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL)

MENLO PARK, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today reported financial results and operational highlights for the first quarter ended March 31, 2022. “We made steady progress with the clinical development of our lead asset ADI-001 during the first quarter of 2022 and look forward to reporting updated

Adicet Reports First Quarter 2022 Financial Results and Provides Business Updates

MENLO PARK, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced data from a preclinical evaluation of ADI-001 at the International Society for Cell and Gene Therapy (ISCT) Annual Meeting taking place in San Francisco, May 4-7, 2022. ADI-001 is currently being evaluated in an ongoing dose escalation Pha

Adicet Presents Preclinical Data at the ISCT Annual Meeting Highlighting Potential Advantages of the Non-Gene-Edited Approach for its Investigational Allogeneic Gamma Delta CAR T Cell Therapy Targeting CD20 for B Cell Malignancies

Adicet Bio, Inc. (ACET) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Adicet Bio, Inc. (ACET) Surges 6.8%: Is This an Indication of Further Gains?

MENLO PARK, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that updated safety and efficacy data from the Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphoma (NHL) will be delivered as an oral presentation at the upcoming 2022 American Socie

Adicet Bio Announces Oral Presentation of Updated ADI-001 Phase 1 Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

MENLO PARK, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its lead program ADI-001, an investigational therapy targeting CD20 for the potential treatment of relapsed or refractory B-cell Non-Hodgkin's lymphoma (NHL)

Adicet Bio Receives FDA Fast Track Designation for Lead Candidate ADI-001

Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of -6.82% and 17.59%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Adicet Bio, Inc. (ACET) Reports Q4 Loss, Tops Revenue Estimates

MENLO PARK, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2021. “2022 marks an exciting new chapter for Adicet. Our clinical and operational accomplishments in the fourth quarter of 2021, including the

Adicet Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress

Adicet Bio (ACET) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Adicet Bio (ACET) This Earnings Season?

Adicet Bio, Inc. (ACET) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Adicet Bio, Inc. (ACET) Expected to Beat Earnings Estimates: Should You Buy?

The company's platform is based on gamma delta 1 T cells, which have been major investor attention recently. The next data update from the above ADI-001 FIH study is expected in mid this year (likely at the EHA conference from June 9-12 (the next key catalyst).

Adicet Bio: Gamma Delta 1 CAR-T Technology And A Takeover Candidate

Amgen

AstraZeneca

These companies' share prices could rise in the short term, but their long-term opportunities are even better.

3 Biotech Stocks That Could Make You Richer in February (and Beyond)

MENLO PARK, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2022 Oncology Conference taking place virtually on February 9-11, 2022. Details of the event are as follows: Date: Wednesday, February 9, 2022 Time: 11:30 am ET A live

Adicet Bio to Participate in Guggenheim 2022 Oncology Conference

Chemocentryx

NRX Pharmaceuticals

They're risky. But with the high risk comes the potential for high rewards.

3 Biotech Stocks That Could Double in 2022

MENLO PARK, Calif. and BOSTON, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer and other diseases, today announced the closing of its previously announced underwritten public offering of 7,187,500 shares of its common stock, including the exercise in full by the underwriters of their option to purchase up to an additional 937,500 shares of common stock, at a public offering price of $14.00 per share, less underwriting discounts and commissions. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $100.6 million. All of the shares in the offering are were sold by Adicet.

Adicet Bio, Inc. Announces Closing of $100 Million Public Follow-On Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

Adicet Bio Inc (NASDAQ: ACET) priced an underwritten public offering of 6.25 million shares at $14.00 per share, raising gross proceeds of $87.5 million. The offer price represents a discount of almost 3% from the last close price of $14.49 on Tuesday.

Adicet Bio Raises $87M Via Equity To Fund Development Of Non-Hodgkin's Lymphoma Candidate

MENLO PARK, Calif. and BOSTON, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer and other diseases, today announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock at a public offering price of $14.00 per share. Adicet also granted the underwriters a 30-day option to purchase up to an additional 937,500 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $87.5 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares in the offering are to be sold by Adicet. The offering is expected to close on or about December 10, 2021, subject to the satisfaction of customary closing conditions.

Adicet Bio, Inc. Announces Pricing of Public Offering of Common Stock

MENLO PARK, Calif. and BOSTON, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer and other diseases, today announced that it has commenced an underwritten public offering of its common stock. Adicet also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares sold at the public offering price, less underwriting discounts and commissions. All of the shares in the proposed offering are to be sold by Adicet. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Adicet Bio, Inc. Announces Proposed Follow-On Offering of Common Stock

The company reported positive interim results from a phase 1 study.

Why Adicet Bio Stock Is Skyrocketing Today

Adicet Bio Inc (NASDAQ: ACET) has announced positive interim data from its dose-escalation Phase 1 study evaluating ADI-001 for B-cell Non-Hodgkin's Lymphoma.  Adicet's AD-001 is an off-the-shelf cell therapy developed by engineering a CD20-targeting chimeric antigen receptor (CAR) onto a donor's gamma delta T cells.

Adicet Stock Rallies After Early Responses For Off-The-Shelf Drug In B-cell Non-Hodgkin's Lymphoma

The stock price of Adicet Bio Inc (NASDAQ: ACET) increased by over 40% pre-market today. This is why it happened.

Adicet Bio Stock (ACET): Why The Price Surged Today

MENLO PARK, Calif. and BOSTON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta CAR T cell therapies for cancer and other diseases, today announced positive interim data from its dose escalation Phase 1 study evaluating the safety and tolerability of ADI-001, Adicet's investigational therapy targeting CD20 for the potential treatment of B-cell Non-Hodgkin's Lymphoma.

Adicet Bio Announces Positive Interim Clinical Data From First-Ever Allogeneic, Off-The-Shelf, Gamma Delta CAR T Investigational Cell Therapy

ADI-001 is the first ever allogeneic, off-the-shelf, gamma delta CAR T cell therapy to report clinical data

Adicet Bio to Host Webcast Presentation of ADI-001 Interim Clinical Data in B Cell Non-Hodgkin's Lymphoma

MENLO PARK, Calif. and BOSTON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the appointment of Michael G. Kauffman, M.D., Ph.D., to its Board of Directors.

Adicet Announces Appointment of Dr. Michael G. Kauffman to the Board of Directors

Adicet's allogeneic gamma delta CAR-T cell therapy candidate is designed to combine CAR targeting and cell intrinsic IL-15 armoring with the innate and adaptive immune effector functions of the Company's gamma delta T cell platform

News for Adicet Bio, Inc. Stock (ACET)